Company Overview and News

 
KLCI ticks up in early trade, gains seen capped

41m theedgemarkets
KUALA LUMPUR (Sept 20): The FBM KLCI ticked higher in early trade this morning, tracking gains at the regional markets.
HLFBF 1082 7113 5681 TPGVF BATS 4162 TGLVY 5347 0104 TNABY 5819 TNABF

 
KLCI rises 0.53%, climbs above 1,800-level

2018-09-19 theedgemarkets
KUALA LUMPUR (Sept 19): The FBM KLCI rose 0.53% at mid-morning today and climbed above the 1,800-point level, tracking gains at the regional markets.
HLFBF PBLOF 1082 7113 5681 TPGVF 1295 5168 3794 6033 TGLVY 5238 4588 PNADF 1201 0026 5819 PNAGF HRGHY

 
KLCI falls 0.66% as Trump’s new tariff on China rattles region

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 18): The FBM KLCI fell 0.66% at midday break, as new tariffs announced by Washington on Chinese imports rattled regional markets.
HLFBF 7052 MLYNF 8621 9679 BATS 4162 2089 1783 1023 5225 IHHHF PNAGF HRGHY MLYBY UPBMF 1082 5681 5168 6033 7123 CIMDF 5238 1155 PNADF SGPBY 0026 Q0F

 
KLCI dips 0.39% as select blue chips drag

2018-09-13 theedgemarkets
KUALA LUMPUR (Sept 13): The FBM KLCI dipped 0.39% at mid-morning, dragged by losses at select index-linked blue chips.
HLFBF PBLOF UPBMF 7036 1082 7113 5681 TPGVF BATS 4162 0096 7087 1295 2089 5256 9334 TGLVY 5139 5258 3301 0900 5819

 
KLCI dips 0.55% in line with regional pull back

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 12): The FBM KLCI dipped 0.55% at midday break today, in line with pull back at most regional markets.
4065 7036 7113 5681 TPGVF 0096 9334 6033 7277 7123 5199 TGLVY 5139 5238 PNADF 3026 0900 2836 HIPEF PNAGF 3719

 
KLCI reverses gains, slips below 1,800-level

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 12): The FBM KLCI reversed much of its gains at mid-morning today and slipped below the 1,800-level, in line with wobbly regional markets.
7036 7113 5681 TPGVF 9334 6033 7123 5199 TGLVY KLKBY 5238 2445 PNADF 3026 0118 HIPEF PNAGF 3719

 
KLCI rises 0.77% as banks, select blue chips lift

2018-09-12 theedgemarkets
KUALA LUMPUR (Sept 12): The FBM KLCI rose 0.77% in early trade, lifted by index-linked banking stocks as well other select blue chips.
HLFBF PNADF PBLOF 5183 PECGF 5703 5819 1082 5681 1295 PNAGF 6033

 
PetDag growth to come from lubricant ops on aggressive sales

2018-09-07 thestar.com.my
PETALING JAYA: Petronas Dagangan Bhd ’s (PetDag) growth will likely come from the lubricant segment, with a projected 5% volume growth, following the adoption of a more aggressive sales strategy, said Affin Hwang Capital.
5681

 
Petronas Dagangan up after Affin Hwang initiates coverage

2018-09-06 theedgemarkets
KUALA LUMPUR (Sept 6): Petronas Dagangan Bhd shares rose as much as 32 sen or 1.2% to RM27 so far today after Affin Hwang Investment Bank Bhd initiated coverage on the stock.
5681

 
Does the rally of Petronas-linked counters still have legs?

2018-09-05 theedgemarkets
THE FBM KLCI breached the psychologically critical level of 1,800 points last week. The benchmark index has risen nearly 9% from this year’s low of 1,663.9 on July 6 and has been on an upward trend since the start of the second half of the year.
PNADF 5681 BSMAF PNAGF 6033 1818

 
KLCI pares loss, poised to extend lacklustre run

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): The FBM KLCI pared some of its loss at the midday break today, but looked poised to extend its lacklustre start in September.
HLFBF APEXF PBLOF 7090 SPMXF 7036 1082 5681 BATS 4162 0162 1295 8311 6033 5199 PNADF SPMXY 3026 3301 1368 HIPEF PNAGF

 
Spectre of September ghosts keep haunting KLCI

2018-09-03 theedgemarkets
KUALA LUMPUR (Sept 3): The FBM KLCI remained in negative zone at mid-morning today as key index-linked blue chips retreated, in tandem with most regional markets.
HLFBF UPBMF 1082 5681 BATS 4162 0096 2089 9334 6033 7123 0020 5199 PNADF 7129 6888 AXXTF HIPEF PNAGF

 
KLCI ends August on firm note, up 1.75% on-month

2018-08-30 thestar.com.my
KUALA LUMPUR: The FBM KLCI ended a volatile August on a firm note, with the market seeing the re-entry of foreign funds – but still not in a big way – since the May 9 General Election. For the month, the KLCI is up 1.75% or 31.3 points to end at 1,819.66. However, the 30-stock index is still way off the all-time closing high of 1,895 on April 19. At 5pm on Thursday, the KLCI was down 0.98 of a point to 1,819.
PBLOF BRDBF 4065 7113 4197 5681 TPGVF 1295 6033 5210 TGLVY PNADF SMEBF 5819 PNAGF

 
KLCI snaps winning streak as Digi, Hartalega slump

2018-08-29 thestar.com.my
KUALA LUMPUR: The FBM KLCI closed lower on Wednesday as funds took profit on Digi, Hartalega and IHH Healthcare amid a weaker broader market but stocks in focus were Bumi Armada , FGV Holdings and Supermax. At 5pm, the KLCI was down 6.26 points or 0.34% to 1,820.64. Turnover was 2.69 billion shares valued at RM2.63bil. Decliners beat advancers 629 to 355 while 337 counters were unchanged. Global stocks faltered on Wednesday as optimism over a US-Mexico trade deal faded with investors anxious about Canada’s acquiescence and eyeing a deadline for the next round of China-U.
PBLOF BRDBF 4065 4197 5681 1295 6033 5210 PNADF 5225 SMEBF 5819 Q0F IHHHF PNAGF

 
Cautious start for Bursa as KLCI slips in early trade

2018-08-29 thestar.com.my
KUALA LUMPUR: Blue chips fell early Wednesday as investors turned cautious ahead of the US-China tariffs deadline and amid disappointing corporate results for the quarter ended June 30.
5681

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...